Prostamax

1. Overview

Prostamax is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Pro (KEDP) and a molecular weight of 487.50 g/mol (C20H33N5O9). Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology during the 1980s-1990s, it was derived from prostate tissue extracts and is classified as a prostate-targeted peptide bioregulator [6][7].

Prostamax shares the Lys-Glu-Asp (KED) core sequence with several other Khavinson peptides: Pancragen (KEDW, Lys-Glu-Asp-Trp) and Livagen (KEDA, Lys-Glu-Asp-Ala) differ only in their C-terminal amino acid [4]. This structural similarity, combined with distinct tissue-targeting properties, illustrates the Khavinson group's hypothesis that the C-terminal residue determines tissue specificity while the shared KED core provides common epigenetic regulatory activity [3][4].

The peptide's most characterized effects include chromatin decondensation in aged human lymphocytes (specifically pericentromeric structural heterochromatin of chromosome 1), anti-inflammatory activity in rat prostatitis models, and stimulation of reparative processes in prostatic organotypic tissue cultures [1][2]. All published research originates from the Khavinson research network, and no human clinical trials have been conducted or registered. Prostamax has one of the thinnest evidence bases among the Khavinson bioregulator peptides, with most data appearing in comparative multi-peptide studies rather than dedicated investigations.

Sequence

Lys-Glu-Asp-Pro (KEDP)

Molecular Formula

C20H33N5O9

Molecular Weight

487.50 g/mol

Type

Synthetic tetrapeptide (Khavinson prostate bioregulator)

Source

Synthetic analog of peptide isolated from prostate tissue extracts

Mechanism

Chromatin decondensation (pericentromeric heterochromatin of chromosome 1); ribosomal gene reactivation; anti-inflammatory; epigenetic regulation via DNA/histone interaction

Routes Studied

Intramuscular (rats), in vitro (cell cultures, organotypic explants)

FDA Status

Not approved; no clinical trials registered on ClinicalTrials.gov

Related Peptides

Livagen (KEDA), Epithalon (AEDG), Pancragen (KEDW)

2. Mechanism of Action

Prostamax is proposed to act through epigenetic modulation of gene expression, with effects mediated by direct interaction between the peptide and nuclear components including DNA and histone proteins.

Chromatin Decondensation

The primary characterized mechanism of Prostamax is its effect on chromatin structure in cells from elderly individuals. In a 2004 study comparing five Khavinson peptides (Vilon, Epithalon, Livagen, Prostamax, and Cortagen) in leukocytes from subjects aged 75-88 years, all five peptides induced activation of ribosome genes, decondensation of densely packed chromatin fibrils, and release of genes repressed by age-specific condensation of euchromatic regions [1].

Prostamax specifically induced decondensation of chromosome 1 pericentromeric structural chromatin [1]. This effect is partially shared with Livagen and Epithalon, which induce pericentromeric decondensation of both chromosomes 1 and 9, while Prostamax's effect appears more selective for chromosome 1 [1][2]. The functional significance of chromosome-specific decondensation remains unclear, though pericentromeric regions contain satellite DNA sequences that may regulate gene expression in cis across large chromosomal domains.

Ribosomal Gene Reactivation

Like other Khavinson peptides, Prostamax activates ribosomal genes at nucleolus organizer regions through de-heterochromatinization [1][2]. Ribosomal genes encode the RNA components of ribosomes and are essential for protein synthesis capacity. Their progressive silencing through age-related heterochromatinization is proposed to contribute to the decline in cellular function observed with aging [1][2][5].

Peptide-DNA and Peptide-Histone Interaction

The KEDP tetrapeptide is proposed to penetrate cell membranes and interact directly with DNA sequences and histone proteins in the nucleus [3][8]. Fluorescence-labeled short peptides have been shown to penetrate into HeLa cell nuclei [8], and molecular modeling studies have demonstrated energetically favorable binding of short peptides to specific DNA sequences and histone proteins H1, H2b, H3, and H4 [3].

Experimental evidence suggests Prostamax may be associated with an increase in sister chromatid exchanges and nucleolus organizer region activity, corresponding to shifts in ribosomal RNA gene expression and loosening of compacted chromatin domains [1][5].

Anti-Inflammatory Mechanisms

In preclinical rat models of prostatitis, intramuscular KEDP reduced inflammatory markers including tissue swelling, vascular congestion, and immune cell infiltration [7]. The anti-inflammatory mechanism has not been fully elucidated but is proposed to involve modulation of inflammatory gene expression through the same epigenetic pathway that governs chromatin decondensation [3][12].

3. Researched Applications

Prostatitis and Prostatic Inflammation

Evidence level: Preclinical (animal studies)

The most tissue-specific application of Prostamax involves its anti-inflammatory effects in models of prostatic inflammation. In rat models of experimentally induced prostatitis, intramuscular KEDP administration reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue [7]. Specific findings included reduced swelling, decreased vascular congestion, and lower immune cell infiltration in the prostate [7]. These effects suggest potential relevance to chronic prostatitis (CP/CPPS), a common condition affecting up to 15% of men that is characterized by persistent prostatic inflammation and pelvic pain.

Benign Prostatic Hyperplasia

Evidence level: Preclinical (limited data)

Studies in benign prostatic hyperplasia (BPH) models have reported favorable effects on prostate weight and histological parameters [7]. BPH is characterized by non-malignant prostatic enlargement driven by hormonal and inflammatory factors, and the prevention of fibrotic changes by Prostamax could theoretically slow disease progression. However, the specific data are limited and have not been published in detail in peer-reviewed English-language journals.

Chromatin Reactivation in Aging

Evidence level: In vitro (human lymphocytes)

Prostamax's effects on aged chromatin structure are well-documented through multiple comparative studies [1][2][5]. The activation of ribosomal genes and decondensation of heterochromatin in lymphocytes from elderly subjects represents a general anti-aging effect shared with other Khavinson peptides. While this effect is not prostate-specific (it was observed in peripheral blood lymphocytes), it suggests a broader geroprotective mechanism that may contribute to tissue maintenance and repair capacity.

Organotypic Tissue Culture Studies

Evidence level: In vitro (tissue explants)

In organotypic models using prostate tissue explants, Prostamax stimulated reparative processes, with effects observed in both younger and older tissues [7]. The peptide appeared to mitigate age-related tissue deterioration, potentially reducing chronic inflammation and preventing sclerotic or atrophic changes in prostatic tissue [7]. These explant studies bridge the gap between isolated cell culture experiments and whole-organism animal studies.

4. Clinical Evidence Summary

No human clinical trials have been conducted with Prostamax. All evidence derives from in vitro human lymphocyte studies, organotypic tissue cultures, and animal models of prostatitis.

5. Dosing in Research

No standardized human dosing has been established for Prostamax. Commercially available preparations are typically marketed as lyophilized powder in 20 mg vials or oral capsules containing 200 ug per capsule. Anecdotal protocols commonly suggest subcutaneous injection of 100-200 ug daily for 10-20 days, or 1-2 capsules daily for 20-30 days, with courses repeated every 3-6 months. None of these protocols have been validated in controlled human studies.

6. Structural Comparison with Related KED-Core Peptides

Prostamax shares the Lys-Glu-Asp (KED) core with two other Khavinson tetrapeptides, differing only in the C-terminal residue:

| Peptide | Sequence | C-Terminal | Target Tissue | MW (g/mol) | |---|---|---|---|---| | Prostamax | KEDP | Proline | Prostate | 487.50 | | Pancragen | KEDW | Tryptophan | Pancreas | 576.25 | | Livagen | KEDA | Alanine | Liver | 461.47 |

All three peptides induce chromatin decondensation in aged lymphocytes, but their tissue-specific effects differ. According to the Khavinson bioregulator theory, the C-terminal amino acid determines tissue specificity by modulating the peptide's DNA-binding selectivity, while the shared KED core provides common chromatin-remodeling activity [3][4]. This hypothesis is consistent with molecular modeling data showing that peptide-DNA binding energy depends on both the peptide sequence and the DNA target sequence [3].

The KED tripeptide (without any C-terminal extension) has also been studied independently, particularly in the context of neuroprotection and Alzheimer's disease, where it demonstrates effects distinct from but complementary to the EDR (Pinealon) tripeptide [3].

7. Safety and Side Effects

Published Safety Data

Safety information for Prostamax is extremely limited:

• In vitro studies in human lymphocyte cultures reported no cytotoxic effects at experimental concentrations [1][2]
• Rat prostatitis models did not report treatment-related adverse events [7]
• Organotypic tissue culture studies reported no tissue damage from KEDP exposure [7]

Critical Safety Gaps

Prostamax has one of the weakest safety databases among the Khavinson peptides:

• No formal toxicology studies of any kind have been published
• No pharmacokinetic data on absorption, distribution, metabolism, or elimination
• No reproductive toxicity data
• No drug interaction studies (relevant for patients taking alpha-blockers, 5-alpha-reductase inhibitors, or other prostate medications)
• No studies examining effects on prostate-specific antigen (PSA) levels
• No evaluation of potential effects on prostate cancer risk, which is particularly important given that chromatin remodeling and gene reactivation in prostate tissue could theoretically promote neoplastic transformation
• No independent safety assessment by laboratories outside the Khavinson research network
• The effects of sustained chromatin decondensation specifically in prostate tissue have not been evaluated for oncogenic potential

Theoretical Oncologic Concern

Given that prostate cancer is the most common non-skin malignancy in men and involves dysregulated gene expression in prostate cells, any agent that alters prostate cell gene expression through epigenetic mechanisms warrants careful evaluation for cancer risk. The proposed mechanism of Prostamax -- reactivation of silenced genes through chromatin decondensation -- could theoretically reactivate oncogenes if gene silencing served a tumor-suppressive function. No studies have addressed this concern.

8. Regulatory Status

Prostamax is not approved by the FDA, EMA, or any major Western regulatory agency. No clinical trials are registered on ClinicalTrials.gov or any other international trial registry. It is available from research chemical suppliers and as a dietary supplement component in some jurisdictions. The parent prostate polypeptide extract (from which KEDP was derived) has been used in Russian clinical settings but does not have formal pharmaceutical registration comparable to some other Khavinson preparations such as Thymalin or Cortexin.

9. Limitations

The evidence base for Prostamax has critical limitations that should be considered:

• All published research originates from the St. Petersburg Institute of Bioregulation and Gerontology and affiliated institutions in Georgia
• No independent replication by laboratories outside the Khavinson research network
• The most specific prostate-related effects (anti-inflammatory, anti-fibrotic) are described primarily in summary form in reviews rather than in detailed peer-reviewed original research articles accessible in English
• The chromatin decondensation data, while published in peer-reviewed journals, were obtained in peripheral lymphocytes rather than prostate cells, making the tissue-specificity claims extrapolative
• The proposed mechanism of action (direct peptide-DNA binding as a gene regulatory mechanism) remains outside mainstream molecular biology
• No human data of any kind exist for Prostamax

10. Pharmacokinetics

No pharmacokinetic studies have been published for Prostamax (KEDP). As a tetrapeptide of 487.50 g/mol, it faces the standard rapid proteolytic degradation and low oral bioavailability expected for unmodified short peptides.

The proline residue at the C-terminus may confer modest carboxypeptidase resistance compared to tetrapeptides ending in other amino acids, as proline's cyclic structure creates steric constraints for exopeptidase binding. This is shared with Cortagen (AEDP) and potentially provides a slight pharmacokinetic advantage within the Khavinson tetrapeptide family. However, no half-life measurements have been published to quantify this theoretical benefit.

The prostate gland is the proposed target tissue. As a well-vascularized organ, it is accessible via systemic circulation. However, delivery of intact tetrapeptide to prostatic epithelial cells requires survival of plasma proteolysis, transit through prostatic capillary endothelium, and penetration of the prostate-blood barrier. In the context of prostatitis (the primary studied application), inflammatory changes in the prostate may actually increase vascular permeability, potentially facilitating peptide access. This speculative advantage has not been studied.

The rat prostatitis studies used intramuscular injection, which provides higher systemic bioavailability than oral capsules. No data exist comparing oral versus injectable Prostamax for prostatic tissue levels or anti-inflammatory effects.

11. Dose-Response

No dose-response studies have been conducted for Prostamax. The chromatin decondensation studies used experimental concentrations in lymphocyte cultures without titration [1][2]. The rat prostatitis study used a single dosing regimen without dose comparison [7].

The commercially referenced protocols (100-200 ug daily subcutaneously for 10-20 days, or 200 ug oral capsules for 20-30 days) lack any dose-finding justification. No studies have compared different doses for anti-inflammatory endpoints, chromatin remodeling extent, or any clinical parameter.

The relationship between dose and the magnitude of chromosome 1 pericentromeric heterochromatin decondensation is unknown. Whether the effect is all-or-nothing at a threshold concentration or dose-proportional has not been investigated. This is particularly relevant because the clinical significance of chromatin decondensation in circulating lymphocytes for prostate tissue function is itself unestablished.

12. Comparative Effectiveness

Prostamax (KEDP) vs. Pancragen (KEDW) and Livagen (KEDA)

These three tetrapeptides share the KED core and differ only at position 4 (Pro, Trp, Ala). Pancragen has substantially more evidence including primate studies and a human clinical study, while Livagen has chromatin remodeling data and enkephalinase inhibition. Prostamax has the thinnest evidence base of the three, with most data appearing in comparative multi-peptide studies rather than dedicated investigations [1][2]. Whether the proline at position 4 genuinely confers prostate specificity or whether KEDP would produce similar effects in liver (Livagen's target) or pancreas (Pancragen's target) has not been tested.

Prostamax vs. Conventional Prostatitis Treatments

Standard management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) includes alpha-blockers (tamsulosin), antibiotics, NSAIDs, 5-alpha-reductase inhibitors, and physiotherapy. These have varying levels of RCT evidence. Prostamax proposes a fundamentally different mechanism (epigenetic gene regulation) with zero human data. The anti-inflammatory and anti-fibrotic effects observed in rat models [7] are conceptually relevant to CP/CPPS, but no comparative data exist.

Prostamax vs. Prostatilen

Prostatilen is a bovine prostate extract preparation that has achieved pharmaceutical registration in Russia -- it represents the crude extract from which Prostamax was derived. Prostatilen has a larger clinical evidence base and regulatory approval, while Prostamax offers molecular precision as a defined single peptide. The relationship is analogous to Cortexin (extract) versus Cortagen (synthetic peptide).

13. Enhanced Safety

Safety information for Prostamax is extremely limited, representing one of the weakest safety databases among Khavinson peptides. No cytotoxic effects were observed in lymphocyte cultures [1][2], and rat prostatitis models showed no adverse events [7].

The oncological safety consideration is particularly acute for a prostate-targeted agent. Prostate cancer is the most common non-skin malignancy in men, and any agent that alters gene expression in prostate tissue through chromatin remodeling warrants rigorous cancer risk assessment. The reactivation of silenced genes through heterochromatin decondensation could theoretically reactivate oncogenes, and no carcinogenicity studies have been conducted. No effects on PSA levels have been measured.

The anti-fibrotic properties observed in rat prostatitis models [7] could theoretically be beneficial or harmful depending on context. While prevention of prostatic fibrosis may improve symptoms in chronic prostatitis, interference with normal wound healing or tissue remodeling in the prostate could have unintended consequences.

No drug interaction studies have been performed. Patients with prostate conditions may be taking alpha-blockers, 5-alpha-reductase inhibitors (finasteride, dutasteride), or antiandrogens -- interactions with any of these are unknown. No reproductive toxicity data exist, which is particularly concerning for an agent targeting male reproductive tissue. No independent safety assessment has been conducted outside the Khavinson research network.

14. Related Peptides

See also: Livagen, Epithalon, Pancragen, Ovagen, Thymalin

15. References

1. [1] Khavinson VKh, Lezhava TA, Monaselidze JR, Jokhadze TA, Dvalishvili NA, Bablishvili NK, Trofimova SV. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine. DOI PubMed
2. [2] Lezhava TA, Monaselidze JR, Kadzhaia MV, Jokhadze TA, Khavinson VKh. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Medical News. PubMed
3. [3] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
4. [4] Khavinson VKh, Linkova NS, Diatlova AS, Trofimova SV. (2020). Peptide regulation of cell differentiation. Stem Cell Reviews and Reports. DOI PubMed
5. [5] Khavinson VKh, Lezhava TA. (2023). Epigenetic modification under the influence of peptide bioregulators on old chromatin. Advances in Gerontology. PubMed
6. [6] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
7. [7] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
8. [8] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
9. [9] Khavinson VKh, Linkova NS, Kvetnoy IM. (2015). Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Bulletin of Experimental Biology and Medicine. PubMed
10. [10] Morozov VG, Khavinson VKh. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology. DOI PubMed
11. [11] Khavinson VKh, Malinin VV. (2005). Gerontological aspects of genome peptide regulation. Karger Publishers.
12. [12] Kuznik BI, Linkova NS, Khavinson VKh. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences. DOI PubMed
13. [13] Lezhava TA, Jokhadze TA, Monaselidze JR, Khavinson VKh. (2004). Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. PubMed
14. [14] Khavinson VKh. (2020). Peptide medicines: past, present, future. Klinicheskaia Meditsina (Mosk).
15. [15] Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
16. [16] Markova EV, Obukhova LA, Khavinson VKh. (2014). Peptides regulating proliferative activity in the spleen: age-related molecular aspects. Advances in Gerontology. DOI
17. [17] Khavinson VKh, Linkova NS, Kvetnoy IM. (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed